ARTICLE | Company News
DS Biopharma deal
September 5, 2016 7:00 AM UTC
DS Biopharma spun out Afimmune, which will focus on fibrotic and pulmonary diseases. The newco will develop DS Biopharma’s DS102 and other undisclosed preclinical compounds. DS102, a bioactive lipid produced by the non-enzymatic oxidation of eicosapentaenoic acid (EPA), completed Phase I testing in healthy volunteers. Phase IIa testing to treat non-alcoholic steatohepatitis (NASH) is slated to begin later this year. ...